TOXICITY OF CONTINUOUS INFUSION N ACETYL CYSTEINE WITH HIGH DOSE IL2

高剂量 IL2 持续输注 N 乙酰半胱氨酸的毒性

• 批准号: 6304903
• 负责人: WOLFRAM E. SAMLOWSKI
• 金额: $ 0.16万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304903
• 关键词: acetylcysteine; clinical research; clinical trial phase I; combination cancer therapy; combination chemotherapy; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; interleukin 2; intravenous administration; melanoma; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; renal cell carcinoma

Interleukin-2 (IL-2) has established efficacy for the treatment of metastatic or unresectable renal cell carcinoma and malignant melanoma. The effectiveness of Interleukin-2 as an anti-tumor agent likely depends upon the metabolic pathway that leads to the generation of nitric oxide from L-arginine. This study tested the hypothesis that this pathway could be augmented by increasing intracellular concentrations of glutathione by infusing N-acetylcysteine. It was hoped that N-acetylcysteine would increase the activity of IL-2 against the two tumors of interest, and that the toxicity would be acceptable.

白细胞介素-2 (IL-2) 已确定对治疗转移性或不可切除的肾细胞癌和恶性黑色素瘤具有疗效。 Interleukin-2 作为抗肿瘤剂的有效性可能取决于导致 L-精氨酸生成一氧化氮的代谢途径。 这项研究测试了这样的假设：通过注入 N-乙酰半胱氨酸来增加细胞内谷胱甘肽的浓度，可以增强该途径。 人们希望N-乙酰半胱氨酸能够增加IL-2针对两种感兴趣的肿瘤的活性，并且毒性是可以接受的。